The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up
ISRN Immunology · 2012
DOI: 10.5402/2012/324235 ↗Kurz gefasst
Fachartikel in der Zeitschrift ISRN Immunology, 2012. Verfasst von Steven E. Finkelstein und 10 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Radiotherapy (RT) and interferon-alfa-2b (IFN α -2b) have individually been used for adjuvant therapy stage III melanoma with high-risk pathologic features. We hypothesized that concurrent adjuvant RT and IFN α -2b may decrease the risk of regional recurrence following surgery with acceptable toxicity. A prospective multicenter phase I/II study was conducted to evaluate hypofractionated RT with concurrent IFN. Induction IFN α -2b, 20 MU/m 2 /d, was administered IV ×5 consecutive days every week for 4 weeks. Next, RT 30 Gy in 5 fractions was given with concurrent IFN α -2b, 10 MU/m 2 SQ 3 times per week on days alternating with RT. Subsequent maintenance therapy consisted of adjuvant IFN α -2b, 10 MU/m 2 SQ 3 times per week to a total of 1 year. To fully evaluate patterns of failure, long-term follow-up was conducted for up to 10 years. A total of 29 consenting patients were enrolled between August 1997 and March 2000. The maximum (worst) grade of acute nonhematologic toxicity during concurrent RT/IFN α -2b (and up to 2 weeks post RT) was grade 3 skin toxicity noted in 2 patients (9%). Late effects were limited. Probability of regional control was 78% (95% CI: 55%–90%) at 12 months. The median follow-up (range) was 80 (51–106) months among ten survivors (43%). The median overall survival was 34.5 months while the median failure-free survival was 19.9 months. Postoperative concurrent hypofractionated RT with IFN α -2b for advanced stage III melanoma appears to be associated with acceptable toxicity and may provide reasonable in-field control in patients at high risk of regional failure.
Zitieren
APA
Finkelstein, S. E., Trotti, A., Rao, N., Reintgen, D., Cruse, W., Feun, L., Sondak, V., Yu, D., Zhu, W., Gwede, C., & DeConti, R. (2012). The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up. ISRN Immunology. https://doi.org/10.5402/2012/324235
Vancouver
Finkelstein SE, Trotti A, Rao N, Reintgen D, Cruse W, Feun L, et al. The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up. ISRN Immunology. 2012. doi:10.5402/2012/324235
BibTeX
@article{Finkelstein2012,
author = {Finkelstein, Steven E. and Trotti, Andy and Rao, Nikhil and Reintgen, Douglas and Cruse, Wayne and Feun, Lynn and Sondak, Vernon and Yu, Daohai and Zhu, Weiwei and Gwede, Clement and DeConti, Ronald},
title = {The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up},
journal = {ISRN Immunology},
year = {2012},
doi = {10.5402/2012/324235}
}
EUVIMED